Reaction

Jugular Vein Thrombosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,742 reports · 77 co-occurring drugs

As of the last recalculation, Jugular Vein Thrombosis appears in 1,742 FAERS reports alongside 77 co-occurring drug terms. The strongest observed disproportionality signal is DROSPIRENONE AND ETHINYL ESTRADIOL (PRR 43.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Drospirenone And Ethinyl Estradiol	148	43.6	43.8
Pegaspargase	33	32.8	32.9
Heparin Sodium	26	22.9	23.0
Promethazine Hydrochloride	25	16.3	16.3
Granisetron Hydrochloride	14	16.1	16.2
Etonogestrel And Ethinyl Estradiol	29	15.9	15.9
Leucovorin Calcium	25	15.8	15.9
Granisetron	13	14.9	14.9
Tofacitinib Citrate	16	14.7	14.7
Teduglutide	16	14.3	14.3
Posaconazole Delayed-Release	13	14.2	14.3
Phytonadione	10	14.2	14.2
Daspone	11	13.6	13.6
Dapsone Gel, 5%	11	13.6	13.6
Enoxaparin Sodium	63	13.5	13.6
Atropine	9	13.0	13.1
Fluorouracil Cream, 0.5%	79	12.9	12.9
Fluorouracil	80	12.9	12.9
Thiotepa	10	12.6	12.6
Mercaptopurine	18	12.5	12.5
Dapsone	11	12.4	12.4
Cytarabine	58	11.9	11.9
Blinatumomab	10	11.5	11.5
Atropine Sulfate	10	11.1	11.1
Cetuximab	28	10.8	10.8
Fondaparinux Sodium	7	10.4	10.4
Vincristine Sulfate	25	10.3	10.3
Hydroxyurea	18	10.3	10.3
Bisacodyl Suppositories	11	10.2	10.2
Mesna Injection	7	10.2	10.2
Butalbital, Acetaminophen, And Caffeine	9	10.1	10.1
Biscodyl	11	10.1	10.1
Bendamustine Hcl	13	10.1	10.1
Doxorubicin Hydrochloride	27	10.0	10.0
Mesna	7	10.0	10.0
Posaconazole	13	9.6	9.6
Pertuzumab	21	9.3	9.3
Epoetin Alfa	9	9.1	9.1
Paclitaxel (Aibumin-Bound)	59	8.8	8.8
Paclitaxel	68	8.5	8.5
Melphalan	16	8.5	8.5
Panitumumab	11	8.4	8.4
Ibuprofen And Diphenhydramine Citrate	16	8.3	8.3
Melphalan Hydrochloride	17	8.2	8.2
Cyclophosphamide Injection, Solution	112	8.0	8.0
Cyclophosphamide	112	8.0	8.0
Cyclophosphamide For Injection	112	8.0	8.0
Aprepitant	12	7.8	7.8
Carboplatin	77	7.5	7.5
Trastuzumab	42	7.5	7.5
Irinotecan Hydrochloride	8	7.5	7.5
Polatuzumab Vedotin	6	7.4	7.4
Vancomycin	35	7.4	7.4
Doxorubicin	53	7.3	7.3
Romiplostim	9	7.2	7.2
Oxaliplatin	42	6.9	6.9
Etoposide	40	6.6	6.6
Apixaban	35	6.4	6.4
Bevacizumab	63	6.3	6.3
Cisplatin	37	5.8	5.8
Docetaxel Anhydrous	31	5.6	5.6
Docetaxel	31	5.6	5.6
Gemcitabine	17	5.2	5.2
Daptomycin	4	5.2	5.2
Pemetrexed	9	5.0	5.0
Alteplase	6	4.8	4.8
Brentuximab Vedotin	4	4.7	4.7
Gemcitabine Hydrochloride	19	4.3	4.3
Carfilzomib	10	4.2	4.2
Nivolumab	29	3.6	3.6
Abemaciclib	6	3.6	3.6
Trifluridine And Tipiracil	3	3.3	3.3
Osimertinib	8	3.0	3.0
Olaparib	5	2.9	2.9
Dornase Alfa	4	2.4	2.4
Pegfilgrastim	18	2.2	2.2
Adapalene	6	0.4	0.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.